AREXVY, Pulver und Suspension zur Herstellung einer Injektionssuspension

7680693100039 CH-69310 Pulver

No image available

Article details

Package size
10
Selling units
10
Measure
Durchstechflasche(n)
Galenic form
Pulver
Galenic group
Lösbar zur Einnahme

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
28/04/2026
Summary of Product Characteristics
Français
28/04/2026
Summary of Product Characteristics
Italien
28/04/2026

Detailed composition

Substance Quantity Type Category
proteinum prae-fusionatum F viri sincitialis respiratorii
120.0 UG Substance Wirkstoff (Principe actif)
adeps A 3-O-desacyl-4’-monophosphorylatus
- Substance HNIDK
proteinum prae-fusionatum F viri sincitialis respiratorii
120.0 UG Substance Wirkstoff (Principe actif)
trehalosum dihydricum
- Substance HNIDK
trehalosum dihydricum
- Substance HNIDK
Quillajae saponariae Molina saponinum purificatum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
1,2-dioleoyl-sn-glycero-3-phosphocholinum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
kalii dihydrogenophosphas
- Substance HNIDK
cholesterolum
- Substance HNIDK
kalii dihydrogenophosphas
- Substance HNIDK
dikalii phosphas anhydricus
- Substance HNIDK
dinatrii phosphas
- Substance HNIDK
dikalii phosphas anhydricus
- Substance HNIDK
adeps A 3-O-desacyl-4’-monophosphorylatus
- Substance HNIDK
kalii dihydrogenophosphas
- Substance HNIDK
natrii chloridum
- Substance HNIDK
Quillajae saponariae Molina saponinum purificatum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
1,2-dioleoyl-sn-glycero-3-phosphocholinum
- Substance HNIDK
cholesterolum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
dinatrii phosphas
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.78 MG Substance HBESI
kalium
0.35 MG Substance HBESI

Authorization holder

GlaxoSmithKline AG

6340 Baar

Authorization information

Swissmedic authorization number
69310
Drug name
AREXVY, Pulver und Suspension zur Herstellung einer Injektionssuspension
Galenic form
PULSIN
ATC Code
J07BX05
Authorization status
Z
Dispensing category
B
First authorization
02/05/2024
Authorization expiration date
01/05/2029
IT Number
08.08.
Domain
Human medicine
Field of application
Aktive Immunisierung zur Vorbeugung einer durch RSV verursachten Erkrankung der unteren Atemwege von Erwachsenen ≥60 Jahren sowie von Erwachsenen zwischen 50 und 59 Jahren mit einem erhöhten Risiko für eine RSV-Erkrankung

Package details

Description (FR)
AREXVY susp inj 120 µg 10 pce
Description (DE)
AREXVY Inj Susp 120 µg 10 Stk
Market launch
02/05/2024
Narcotic (BTM)
No

Other package sizes (1)

AREXVY subst sèche c solv flac
1 DUR
GTIN: 7680693100015
View
Buy us a coffee Explore the data